Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Eastern Cooperative Oncology Group
AstraZeneca
NRG Oncology
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
Pfizer
Mashhad University of Medical Sciences
National Cancer Institute (NCI)